Prenatal Paracetamol Exposure and Offspring ADHD Risk: A Narrative Review of Evidence, Plausibility, and Implications

Abstract

Background: Paracetamol is the most commonly used analgesic and antipyretic during pregnancy. Concurrently, attention-deficit/hyperactivity disorder (ADHD) is a prevalent neurodevelopmental condition. Recent evidence has raised concerns regarding the potential impact of prenatal paracetamol exposure on offspring ADHD risk.

Objective: To examine the current evidence linking prenatal paracetamol exposure to ADHD, evaluate biological plausibility, and assess clinical and public health implications.

Methods: This narrative review synthesized findings from prospective cohort studies, case–control studies, and meta-analyses published mostly within the past decade and indexed in PubMed, PMC, Lancet.

Results: Several observational cohort studies and meta-analyses report modest associations between prenatal paracetamol exposure and increased risk of ADHD. Meta-analyses and umbrella reviews highlight moderate heterogeneity and substantial vulnerability to residual confounding, particularly confounding by indication and shared familial factors. Importantly, large nationwide cohort studies incorporating sibling-controlled analyses suggest that previously observed relationships may largely reflect genetic, environmental, or maternal health-related confounding rather than causal effects.

Conclusion: Recent reviews emphasize that while observed associations warrant a precautionary approach, the available evidence from observational studies cannot establish a causal link between typical prenatal acetaminophen (paracetamol) use and ADHD diagnosis in children. As such it is still present as first-line treatment, when clinically indicated, used at the lowest effective dose and shortest duration according to regulatory agencies such as EMA.